Cerevel Therapeutics (CERE)
(Delayed Data from NSDQ)
$42.55 USD
-0.04 (-0.09%)
Updated May 3, 2024 04:00 PM ET
After-Market: $42.54 -0.01 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth A Momentum D VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
05/08/2024
Time: -- |
3/2024 | $-0.61 | 0.00% |
Earnings Summary
For their last quarter, Cerevel Therapeutics (CERE) reported earnings of -$0.61 per share, beating the Zacks Consensus Estimate of $-0.63 per share. This reflects a positive earnings surprise of 3.17%. Look out for CERE's next earnings release expected on May 08, 2024. For the next earning release, we expect the company to report earnings of -$0.61 per share, reflecting a year-over-year increase of 8.96%.
Earnings History
Price & Consensus
Zacks News for CERE
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
CERE: What are Zacks experts saying now?
Zacks Private Portfolio Services